|Articles|May 1, 2001

Methotrexate remains mainstay

Washington - As methotrexate reaches the 50th anniversary of its first use as an antipsoriatic agent, it remains the gold standard for patients whose disease requires systemic treatment, Gerald D. Weinstein, M.D., said at the annual meeting of the American Academy of Dermatology.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME